Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for IGM Biosciences, Inc. (IGMS : NSDQ)
 
 • Company Description   
IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences Inc. is based in Mountain View, California.

Number of Employees: 192

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.11 Daily Weekly Monthly
20 Day Moving Average: 376,479 shares
Shares Outstanding: 42.53 (millions)
Market Capitalization: $642.58 (millions)
Beta: -0.13
52 Week High: $99.44
52 Week Low: $12.74
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.80% -12.12%
12 Week -7.02% 0.89%
Year To Date -48.48% -38.74%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
325 EAST MIDDLEFIELD ROAD
-
MOUNTAIN VIEW,CA 94043
USA
ph: 650-965-7873
fax: -
None http://igmbio.com
 
 • General Corporate Information   
Officers
Fred Schwarzer - Chief Executive Officer; President and Director
Michael Loberg - Chair of the Board of Director
Misbah Tahir - Chief Financial Officer
Felix Baker - Director
M. Kathleen Behrens - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 449585108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 42.53
Most Recent Split Date: (:1)
Beta: -0.13
Market Capitalization: $642.58 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.45 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-6.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.40
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -61.05%
vs. Previous Quarter: -2.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -70.14
12/31/21 - -54.67
09/30/21 - -41.37
ROA
03/31/22 - -59.87
12/31/21 - -48.52
09/30/21 - -37.81
Current Ratio
03/31/22 - 7.23
12/31/21 - 8.67
09/30/21 - 13.13
Quick Ratio
03/31/22 - 7.23
12/31/21 - 8.67
09/30/21 - 13.12
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.81
12/31/21 - 7.54
09/30/21 - 8.80
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©